ARC 64170Alternative Names: FPL 64170
Latest Information Update: 18 Jan 2007
At a glance
- Originator AstraZeneca R&D Charnwood
- Mechanism of Action 5-lipoxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis; Ulcerative colitis